G. Sartori

Characterization of a novel humanized heavy chain antibody targeting endogenous retroviruses with anti-lymphoma activity

This study identifies HERV-K as a therapeutic target in DLBCL, develops a humanized nanobody with anti-lymphoma activity, and shows its potential through antibody-dependent cytotoxicity.

The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib

This paper shows that elimusertib, an ATR inhibitor, has anti-lymphoma activity and synergizes with copanlisib, a PI3K inhibitor, in multiple lymphoma models.

ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms

This study identifies ERBB4-mediated signaling as a mechanism of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms and shows that targeting ERBB signaling can restore sensitivity.

A first-in-class Wiskott-Aldrich syndrome protein (WASp) activator with anti-tumor activity in hematological cancers

This paper develops EG-011, a first-in-class WASp activator with anti-tumor activity in hematological cancers, including resistant models.

IL-1α secreted by subcapsular sinus macrophages promotes melanoma metastasis in the sentinel lymph node by upregulating STAT3 signaling in the tumor.

This study shows that IL-1α from subcapsular sinus macrophages promotes melanoma metastasis by enhancing STAT3 signaling in tumor cells, and blocking this pathway reduces metastasis.

The E3 ubiquitin-protein ligase MDM2 is a novel interactor of the von Hippel-Lindau tumor suppressor

This study identifies a novel interaction between pVHL30 and MDM2, showing isoform-specific binding and functional synergy in cell proliferation regulation.